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Helicobacter pylori is a Gram-negative flagellated bacterium that infects the stomach of around 50 % 
of the worlds population, and can give rise to serious disease such as chronic gastritis, duodenal 
ulcer and stomach cancer. The current treatment against H. pylori, consisting of a combination of a 
proton pump inhibitor and two different antibiotics, is effective but has several drawbacks such as 
increased risk of antibiotic resistance and no protection against re-infection. Although extensive 
research is going on to develop a vaccine that would be an attractive alternative or complement to 
the current treatment, there is no vaccine available against H. pylori today. However, in 
experimental models, oral vaccination with selected H. pylori antigens given together with cholera 
toxin as adjuvant can give rise to protective immunity, both when the vaccine is given before 
infection and when administered to already infected animals. Antibodies to a number of antigens 
have been detected in the sera of infected patients, and many of these are known to be virulence 
factors, and are considered as candidate H. pylori vaccine antigens, alone or in a combination. Two 
such antigens are Neutrophil-activating protein (NAP) and Flagellin A (FlaA). The H. pylori NAP, 
localised in the bacterial cytosol, is known to stimulate human neutrophils. H. pylori carry 5-7 
flagella that provide motility required for colonisation and infection. H. pylori  FlaA is the major 
protein and structural subunit of the flagellar filament. Both NAP and flagella preparations induce 
protection against H. pylori infection. Hence, the aim of this thesis work was to purify NAP and 
FlaA to be used for vaccine development purposes. Since preparations enriched by  a specific 
protein are not easily obtained from natural host cells, recombinant protein production is a 
frequently used procedure. Escherichia coli facilitates protein expression by its inexpensive and fast 
high-density cultivation, its relative simplicity and the well-known genetics. 
In this project the H. pylori antigens NAP and FlaA were cloned and expressed in E. coli, and a 
purification strategy were set up for the two proteins. The flaA and napA genes from H. pylori strain 
SS1 were amplified by high fidelity PCR. After TA cloning, the two genes were sequenced, and 
inserted into the expression vector pML-λPL, relying on the heat-induced promoter λPL. The 
recombinant expression vectors were transformed into E. coli N4830I host cells, and the induced 
expression of NAP and FlaA protein was detected on SDS-gels and immunoblots. NAP protein 
produced in heat-induced N4830I-pML-λPL-napA was purified through several steps, including 
ammonium sulphate precipitation, anion exchange chromatography and gel filtration. The FlaA 
protein was produced as inclusion bodies in heat-induced N4830I-pML-λPL-flaA. In conclusion, 
NAP was purified with good quality (high purity), although the yield was limited. Despite that 
several strategies were tested in the attempt to purify FlaA, the protein could not be purified and 
solubilized in its native form. Problems with polymerisation and precipitation suggested that 
alternative strategies should be considered for the future expression and purification of FlaA. 
Further characterisation and optimisation of the protein expression are required to develop highly 
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       Appendix - A1: Buffers and solutions 
     A2: SDS-PAGE 




Amp    Ampicillin
bp    Base pairs 
BSA   Bovine Serum Albumin
Conc.   Concentration
dH2O   destilled water
DMI   Department of Microbiology and Immunology
dNTP   deoxyribonucleoside triphosphate
E. coli   Escherichia coli
EDTA   ethylene diamine tetraacetic acid
EtBr   Etidium bromide
EtOH   Ethanol
FlaA   Flagellin subunit A
h   hour(s)
HAC   Acetic Acid
H. pylori   Helicobacter pylori
Ig    Immunoglobulin
IPTG    Isopropylthiogalactoside
Kb   kilo base
kDa    kilo Dalton
LB   Luria-Bertani broth
mA   milli-Ampere
mAb    monoclonal antibody
mM   milli-Molar
NAP   Neutrophile-activating protein 
nm    nano meter
OD   Optical density
PBS   Phosphate Buffered Saline
PCR   Polymerase Chain Reaction
SDS-PAGE  Sodium Dodecyl Sulphate – polyacrylamide gel electrophoresis
SS1   Sydney strain 1
TBE   Tris-borate-EDTA
TBS   Tris Buffered Saline





For a long time, the human stomach was 
considered to be a sterile organ where no 
microorganisms could live due to the harsh 
acidic conditions. This changed in 1982, when 
Warren and Marshall were able to culture 
Helicobacter pylori bacteria from gastric 
biopsies, and found that the bacteria were 
present in patients with active chronic gastritis, 
duodenal ulcer or gastric ulcer (Marshall and 
Warren, 1984). They were later awarded the 
Nobel Prize (in 2005) for their discovery of H. 
pylori and its role in gastritis and peptic ulcer 
disease. The possibility that peptic ulcers 
could be caused by a bacterium, and not stress, 
spicy food or other factors was a surprise to the 
scientific community, and it was difficult for 
Warren and Marshall to change the prevailing 
dogma. To convince colleagues and the public, 
Barry Marshall drank a suspension of 
bacterium and proved Koch´s postulate for 
gastritis. (Marshall, et al., 1985) However, it 
was not until the early 1990s that is was 
recognized that H. pylori causes peptic ulcer 
disease. During that period, several researchers 
confirmed that H. pylori eradication cured 
peptic ulcer (Coghlan et al. 1987, Rauws and 
Tytgat, 1990, Graham et al. 1991). 
In retrospect, it is interesting to notice that 
there were many references to the presence of 
H. pylori in gastric mucosa before its culture in 
1982. Spiral-shaped bacteria were noted many 
times in the literature, but their presence was 
not properly correlated with 
gastro-duodenal disease
(Marshall, 2002,  Mobley et al. 
2001). One of the first well 
known reports of gastric 
helicobacters was done by 
Bizzozero in Turin in 1893 
(Bizzozero, 1893). 
The bacterium was initially 
named Campylobacter 
pyloridis, then C. pylori (after 
correction to Latin grammar). 
In 1989, after DNA sequencing 
and other data had shown that 
the bacterium did not belong to 
the Campylobacter genus, it was placed in its 
own genus, Helicobacter. The name pylōri 
means “of the pylorus”  or pyloric valve (the 
circular opening leading from the stomach into 
the duodenum), from the Greek word 
gatekeeper.(Mobely et al. 2001). Presently, 
over 20.000 articles have been published on 
“helicobacter”, not counting the articles under 
the previous classification of “Campylobacter”. 
Helicobacter pylori
Helicobacter pylori is a spiral-shaped Gram-
negative flagellated bacterium that infects the 
gastric mucosa of more than half of the world’s 
population, making it the most prevalent of all 
bacterial infections. The prevalence in 
developing countries can be as high as 80-90%, 
whereas it is lower in industrialized countries, 
ranging between 10-50 % (Rothenbacker and 
Brenner, 2003). H. pylori is an important cause 
of chronic gastritis, peptic ulcer disease and 
gastric cancer (Goodwin, 1997). The natural 
progression of H. pylori infection is presented 
in fig. 1. Infection usually occurs during 
childhood and causes symptomatic acute 
gastritis in most patients and persists for 
decades or life-long. The infection can take 
multiple courses. Most people infected with H. 
pylori will never develop symptomatic disease. 
10-15 % will develop peptic ulcer disease 
(gastric or duodenal ulcers), approximately 1% 
will develop gastric adenocarsinoma, and a 
small group of patients will develop gastric 




Fig. 1. Natural progression of H. pylori infection (adapted from figure 1, 
Sauerbaum and Josenhans, 2007).   
The current treatment against Helicobacter 
pylori infection consists of a combination of 
two antibiotics and a proton pump inhibitor. 
The major drawbacks to this therapy are high 
cost, poor  patient compliance and risk of 
developing antibiotic resistance. Furthermore, 
such treatment does not protect against 
reinfection. Extensive research is going on to 
develop a vaccine against H. pylori that will 
have (a) prophylactic use to prevent infection 
and/or (b) therapeutic use to eradicate an 
ongoing infection. A prophylactic vaccine 
would primarily be useful in young children in 
high endemic areas, whereas a therapeutic 
vaccine may be the most relevant one for 
treatment for those that are already infected 
(Svennerholm and Lundgren, 2006). Anti-
bodies to a number of antigens such as UreB, 
VacA, CagA, HpaA, NAP, FlaA and FlaB 
havebeen detected in the sera of infected 
patiens, and many of these virulence factors are 
considered as candidate vaccine antigens, alone 
or in a combination. In experimental models, it 
has been shown that oral vaccination with 
selected H. pylori antigens given together with 
cholera toxin as adjuvant can give rise to 
protective immunity, both when the vaccine is 
given before infection and when administered 
to already infected animals (Nyström and 
Svennerholm 2007, Kabir., 2007).
Neutrophil-activating protein
The H. pylori neutrophil-activating protein 
(NAP) has been shown to be highly 
immunogenic in mice and humans (Satin et al., 
2000), and is suggested to play a central role in 
the accumulation of neutrophils at the site of 
infection. NAP has been shown to be capable 
of binding iron in vitro, increase the adhesion 
of neutrophils to endothelial cells, and induce 
migration and activation of human neutrophils 
and monocytes (summarized by Zanotti et al., 
2002). In addition, H. pylori NAP is described 
as a key factor driving T helper (Th) 1 
inflammation in the H. pylori infection 
(D’Elios et al., 2007), and has been shown to 
be a protective antigen in an H. pylori infection 
model (Satin et al., 2000). Previous 
spectroscopic and electron microscope studies 
suggested that NAP was comparable with a 
four-helix bundle protein oligomerizing to 
form a dodecamer structurally  similar to the E. 
coli DNA-binding protein Dps (Grant et al., 
1998, Tonello et al., 1999). In 2002, the three-
dimensional atomic structure of NAP was 
resolved, confirming that NAP is a 
dodecameric protein, about 90 Å in diameter, 
with 32 symmetry. The arrangement of the 
twelve 17 kDa monomers give rise to a nearly 
spherical shell, with an internal cavity for iron 
accumulation. (Zanotti et al., 2002). The 
structure of H. pylori NAP is shown in fig. 2.
Fig. 2. Structure of H. pylori Neutrophil-activating
protein (Zanotti et al., 2002).
Flagellin A
The bacterial flagellum is both a motor 
organelle and a protein export/assembly 
apparatus that extends from the cytoplasm to 
the cell exterior. The flagellum contains three 
structural elements; the export/switch ring 
complex, the basal body (rod, rings and hook), 
and the filament. The filament is a long, thin 
cylindrical structure that  is helical in shape, 
and therefore when rotated functions like a 
propeller (Macnab., 2003). H. pylori carries 
5-7 flagella that provide motility  required for 
colonization and infection. The flagellum is 
covered with a sheath continuous with the 
bacteria outer membrane, and contains a 
complex filament that is composed of two 
distinctly  different flagellin subunits; FlaA (53 
kDa) and FlaB (54 kDa). Geis et al. first 
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published a report on the purification of  FlaA, 
which is the major subunit of the flagellar 
filament, building up the central and distal 
parts of the H. pylori flagellum. Kostrzynska et 
al. demonstrated that the filament also contains 
a small amount of a second flagellin subunit 
(FlaB) that seems to be located mainly at the 
proximal parts of the filament (Geis et al., 
1989, Kostrzynska et al., 1991). Since the 
motility of H. pylori is an important  virulence 
factor, it has been suggested that FlaA can be a 
potential antigen candidate for a H. pylori 
vaccine (Kabir., 2007). The structure of H. 
pylori has not been resolved, but the structure 
of Salmonella FlaA is presented in figure 3.
Fig. 3. Structure of Salmonella Flagellin A (Lars Brive, 
unpublished)     
Recombinant protein expression
Escherichia coli expression systems
Because of the vast fund of knowledge about 
its genetics, biochemistry, and molecular 
biology, Escherichia coli is the system of first 
choice for expression of many heterologous 
proteins. Genetic manipulations are straight-
forward, cultures of E. coli are easily and 
inexpensively grown, and many foreign 
proteins are well-tolerated and may be 
expressed at high levels (Sambrook and 
Russel, 2001). E. coli expression systems can 
be used for the production of recombinant 
proteins either  intracellularly or extra-
cellularly. Recombinantly expressed proteins 
can in principle be directed to four different 
locations namely the cytoplasm, the periplasm, 
the membrane fraction or the cultivation 
medium. Recombinant expression plasmids 
require a strong transcriptional promoter to 
control high-level gene expression. Promoter 
induction is either thermal or chemical and the 
most common inducer is the sugar molecule 
IPTG. T7 promoter based expression systems 
are often used in recombinant protein 
preparation, but systems using the λPL 
promoter/cI repressor or the tac promoter are 
also common (Sørensen et al., 2005, Terpe., 
2006). The tac promoter is a hybrid between 
the trp and lac promoters. It is stronger than 
either, but still induced by IPTG (De Boer et 
al., 1983, Brosius et al., 1985). The λPL 
promoter is also a very strong promoter. 
Expression vectors that carry the λPL promoter 
are used together with a mutant E. coli host 
that synthesizes a temperature-sensitive form 
of the cI protein. At low temperature (less than 
30°C) this mutant cI protein is able to repress 
the λPL promoter, but at 42°C the protein is 
inactivated, resulting in transcription from the 
promoter (Elvin et al., 1990). The T7 promoter 
is specific for the RNA polymerase coded by 
T7 bacteriophage, and a gene inserted 
downstream of this promoter will be expressed 
at a high level. Expression requires a host 
strain lysogenized by a DE3 phage fragment, 
encoding the T7 RNA polymerase, under the 
control of the IPTG-inducible lacUV5 
promoter. Addition of ITPG to the growth 
medium switches on synthesis of the T7 RNA 
polymerase by triggering the release of 
tetrameric LacI from the lac operator. This in 
turn leads to the transcription of the target gene 
from the T7 promoter, which is initiated by T7 
RNA polymerase (Sørensen et al., 2005, 
Studier and Moffat., 1986).
Inclusion bodies
The expression of foreign proteins at high level 
in E. coli often results in the formation of 
inclusion bodies composed of insoluble 
aggregates of the expressed protein. These 
cytoplasmic granules can be seen with a phase-
contrast microscope and isolated from most 
soluble and membrane-bound bacterial 
proteins. Cells expressing high levels of 
foreign proteins can be concentrated by 
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centrifugation and lysed by mechanical 
techniques, sonication, or lysozyme plus 
detergents. It is crucial to obtain maximal cell 
lysis in order to obtain inclusion bodies in high 
yields. The inclusion bodies are recovered by 
centrifugation and extensively washed. The 
purpose of washing steps is to remove as much 
soluble, adherent bacterial protein as possible 
from the aggregated foreign protein. In most 
cases, adjusting the washing conditions allows 
the isolation of inclusion bodies that contain 
more than 90% pure foreign protein. 
(Sambrook and Russel, 2001) The material 
extracted from the purified inclusion body can 
potentially be used directly as an antigen 
(Harlow and Lane, 1988). 
Protein purification
Protein purification is a series of processes that 
aims to isolate a single type of protein from a 
complex mixture, which is vital for the 
characterisation of the function, structure and 
interactions of the protein of interest. 
Biological tissue or a microbial culture are 
often used as starting material. The various 
steps in the purification process may free the 
protein from a matrix that confines it, separate 
the protein and non-protein parts of the 
mixture, and finally separate the target protein 
from other proteins, which often is the most 
labour-intensive step of protein purification. 
The separation steps exploits differences in 
protein size, physico-chemical properties and 
binding affinity. Initial planning, gathering of 
information and the design of a purification 
strategy are all important prerequisites for a 
successful protein purification. The purpose of 
the protein purification will indicate what is of 
most importance, whether one wants to achieve 
the highest possible quality (protein purity), 
quantity (protein yield) or cost-effectiveness. 
A purified protein can for example be used for 
sequencing and identification, antibody 
production, functional (kinetics) or structural 
(crystallography) studies, physico-chemical 
characterisation methods, or in vivo studies. 
If possible, all known properties about the 
target protein are collected, such as function, 
stability, localisation, solubility, size, charge 
and known impurities. Then, the purification 
steps are mapped out in detail. Chromato-
graphy techniques takes advantage of the 
different properties of the proteins in the total 
mixture, and can separate proteins based on 
their hydrophobicity (hydrophobic interaction 
chromatography), binding affinity for a specific 
ligand (affinity chromatography), isoelectric 
point (ion exchange chromatography), or their 
size and shape (gel filtration). The two latter 
techniques are used in this study, and are 
therefore described in more detail.
Ion exchange (IEX) chromatography
An ion exchange column separates proteins 
based on their isoelectric point (pI). Most 
biomolecules are charged due to presence of 
ionic groups within their structure. The pH 
value at which a biomolecule carries no net 
charge is called the isoelectric point (pI), which 
is specific for each biomolecule. When exposed 
to a pH below its pI, the biomolecule will carry 
a positive charge, and above its pI, a negative 
charge. At a given pH value, a typical sample 
contains a mixture of molecules carrying 
different net charge of varying strength. To 
separate the components, the sample can be 
applied to an ion exchange column packed 
with gel bearing either negative charges (cation 
exchanger) or positive charges (anion 
exchanger). Molecules that carry a net charge 
opposite to that of the gel will bind to the gel 
by electrostatic forces, molecules that carry the 
same or no net charge will pass through. The 
binding of molecules to the column is 
reversible, as each molecule is normally 
displaced and selectively eluted from the 
column by an increasing salt gradient or by 
changing the pH. There are several advantages 
with ion exchange chromatography; it is easy 
to use and results can be predicted. Also, since 
the method involves high loading capacity, and 
concentrates the sample, it can be used as an 
early purification. It is however important to 
note that the choice of eluent and gradient is 
critical. In this study, the anion exchange 
column Resource Q, is used.
Gel filtration (GF)
A gel filtration column separates proteins based 
on their size and shape. A gel filtration column 
is packed with a gel which comprises porous 
beads, e.g. highly cross-linked agarose. When a 
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sample is passed down the column, separation 
depends on the different abilities of the sample 
components to enter the pores within the gel 
beads. Larger molecules, which cannot enter 
even the largest pores, pass through the column 
fastest. Smaller molecules, which can enter the 
pores freely, are delayed to different degree 
during the passage through the gel, depending 
on their size and shape. Proteins are therefore 
eluted in order of decreasing size. The 
advantages of gel filtration are that the method 
is easy to use, it provides free choice of eluent, 
works almost always, and the result is easy to 
predict. Due to limitations such as low 
resolution and small sample volume, this 
chromatography technique is preferably used 
as an intermediate, or final purification step. 
Also, it should be noted that influence of flow 
rate, and column efficiency, plays important 
roles. In this study, the gel filtration column 
Superdex 200, is used.
Background for this study
In 2007 the project “Cloning and expression of 
the Helicobacter pylori antigens NAP and 
FlaA in E. coli”  was performed (Ingrid Lea, 
unpublished). One aim of the project was to 
compare the effects of three different 
expression systems based on either the tac 
promoter, the T7 promoter or the λPL promoter. 
As a result  of the project work, five 
recombinant E. coli strains, in which 
expression of recombinant H. pylori proteins 
could be induced, were successfully 
constructed (two for the expression of NAP 
and three for the expression of FlaA). NAP was 
expressed from the pRSET (T7 promoter) 
vector in E. coli BL21DE3 and from the pML-
λPL vector (λPL promoter) in E. coli N4830I, 
while FlaA, in addition to the two 
abovementioned expression systems, also was 
expressed from the pML vector (tac promoter) 
in E. coli BL21. We concluded that the heat-
induced N4830I-pML-λPL expression system 
was superior to the other systems in the case of 
both NAP and FlaA expression, because it 
provided a high-level expression of NAP, the 
best FlaA expression observed, and the best 
target protein/total protein ratio. Bacteriophage 
λPL promoter based vector systems have also 
previously  been shown to be very  efficient  and 
convenient for the expression of foreign genes, 
and it  has been suggested that the heat-
inducibility of the λPL promoter makes it 
especially attractive for large-scale production 
and purification of gene products (Cheng and 
Patterson, 1992). This, together with the 
observations made in the described project, 
suggested that the expression system based on 
the heat-induced λPL promoter should be the 
first choice for production and purification of 
the H. pylori antigens NAP and FlaA. 
In this study, the H. pylori antigens NAP and 
FlaA were expressed in the N4830I-pML-λPL 
system. The purification strategies to develop 
protein purification protocols for the two 
proteins, included optimisation of protein 
expression and cell disruption, separation by 
precipitation and/or centrifugation techniques, 
and chromatography as final purification steps. 
NAP was purified by a combination of 
ammonium sulphate precipitation, anion 
exchange chromatography and gel filtration. 
FlaA was isolated as inclusion bodies. 
However, no downstream purification was 
possible due to problems with re-precipitation.
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Aims of the thesis
The overall aim of this project was to purify the Helicobacter pylori antigens NAP (Neutrophil- 
activating protein) and FlaA (Flagellin A) obtained from recombinant expression in E. coli.
The specific aims were: 
• To characterize and optimise the expression of recombinant NAP and FlaA in an E. coli 
expression system based on the λPL promoter.
• To establish protein purification protocols for NAP and FlaA that lead to purified proteins of good 






Buffers and solutions used in this study are described in 
the appendix, table A1. 
Cells culture, vector, and growth media
The expression vector pML-λPL was kindly provided by 
Mike Lebens at the Department of Microbiology and 
Immunology. NAP and Flagellin A proteins were 
expressed from this vector under the control of the heat-
induced λPL promoter, and E. coli N4830I was used as 
host. Cells were grown at 30 ºC on LB liquid medium 
and LB plates containing 100 µg/ml Amp.
Methods
Cloning of the H. pylori napA and flaA genes 
Polymerase chain reaction
The flaA and napA genes from H. pylori strain SS1 were 
amplified by high fidelity PCR (2 min at 94 ºC, 5 cycles 
of 30 s at 94 ºC, 30 s at 50 ºC and 1 min at 72 ºC, 20 
cycles of 30 s at 94 ºC, 30 s at 62 ºC and 1 min at 72 ºC, 
and finally 7 min at 72 ºC)  using gene specific primer 
pairs where sites for the restriction enzyme BsaI were 
added. The flaA gene was amplified using the primers 
BsaI-FlaA-f (5’-CGGTCTCGAATTCTATAACAAGGA 
GTTACAACAATGGCT-3’)  and BsaI-FlaA-r (5’-CGG 
TCTCAAGCTTACAAACACCTTTCTCAAAACTAA
GT3-’). The napA gene was amplified using the primers 
BsaI-NAP-f (5’-C GGTCTCGAATTCAAAAGGACTT 
TTGATGAAAACATTTGA-3’) and BsaI-NAP-r (5’-C 
GGTCTCAAGCTTTTAAGCTAAATGGGCTTCTAGC
AT-3’). The start and stop codons are marked in bold. 
The Expand High Fidelity PCR System (Roche) was 
used in a 20 µl PCR reaction that consisted of 0.5 µl 
dNTP, 2.5 µl MgCl2, 2.5 µl buffer (with MgCl2), 0.75 µl 
of each primer, 0.5 µl enzyme, and dH2O. 250 ng 
genomic DNA from H. pylori SS1 strain was added as 
template. The TrueStart™ Taq PCR System (Fermentas) 
was used to verify the presence of correct inserts in all 
cloning and transformation steps. The 25 µl PCR 
reaction consisted of 0.5 µl dNTP, 2.5 µl buffer, 4 µl 
MgCl2, 0.75 µl of each primer, 0.15 µl enzyme, and 
dH2O. The bacterial colony to be screened was added as 
template.
Agarose gel electrophoresis 
Agarose gel electrophoresis was used to check PCR-
products, ligation products or DNA cut with restriction 
enzymes. 9 g DNA grade agarose was dissolved in 60 ml 
0.5 % TBE buffer to make a 1.5 % agarose gel and the 
gel was left to polymerise for 30 minutes. The samples 
to be run on the gel were mixed with gel loading buffer, 
and 10 µl was loaded into each of the wells. 6 µl of 1 Kb 
DNA ladder or 100 bp DNA ladder from Fermentas 
(Appendix, fig. A2 / A3) was used as standard. The gel 
was run in 0.5 % TBE buffer at 100 V for 0.5 - 1.0 h, 
depending on the degree of separation needed. The gel 
was stained with EtBr, and the DNA bands were 
visualised by exposing the gel to UV light.
TOPO TA cloning
The PCR products amplified by High Fidelity PCR were 
ligated into a cloning vector using the TOPO TA cloning 
Kit from Invitrogen. A cloning reaction of 1 µl fresh 
PCR product, 1 µl diluted salt solution, 1 µl pCR 2.1-
TOPO vector and 3 µl H2O was mixed gently, incubated 
for 20 minutes at room temperature and placed on ice 
until transformation into bacteria. 
 
Transformation of competent bacteria
The competent E. coli cells were thawed on ice. 1 µl 
ligation reaction and 40 µl competent cells were mixed 
in a cuvette on ice. The samples were electroporated at 
2.5 V, and 250 µl of LB medium was immediately added 
to the cells. The mixture was transferred to a tube, and 
incubated at 30 °C on a shaker for 1 h. The 
transformation mixture was spread on pre-warmed 
LB-Amp plates. The plates were incubated overnight at 
30 °C, and analysed by PCR screening.
Plasmid Miniprep and Determination of DNA 
concentration
Plasmids were isolated from bacterial culture using the 
GeneJET™ Plasmid Miniprep Kit from Fermentas. The 
over-night culture was centrifuged at 5000 x g for 10 
minutes, and the resulting pellet was used to extract 
plasmid DNA according to the GeneJET™ Plasmid 
Miniprep Protocol. The concentration of the DNA 
extracted from the Plasmid Mini-prep procedures was 
measured by using the NanoDrop ND-100 
Spectrophotometer.
DNA Sequencing
Target sequences were sequenced after cloning into pCR 
2.1 TOPO / XL1. The purified plasmid DNA samples 
were diluted in elution buffer (10 mM Tris-HCl)  and 10 
µl H2O to reach a concentration of 2.5 µg DNA per 20 
µl. The prepared samples were sequenced at Eurofins 
MWG Biotech in Germany, and the resulting sequences 
were analysed by using Blast2.
DNA digestion by restriction enzymes
Plasmid DNA was digested with restriction enzymes in 
buffer G or Tango (Fermentas)  in order to isolate napA 
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and flaA inserts from pCR 2.1 TOPO, and to prepare the 
expression vector for ligation with the napA and flaA 
inserts. The pCR-napA and pCR-flaA plasmids with 
inserts generated from PCR amplification using gene 
specific primers were cut with BsaI  in  buffer G in order 
to create napA and flaA inserts with EcoRI/HindIII 
overhangs. The expression vector pML-λPL (Appendix, 
fig. A4) was opened with EcoRI (Fermentas) and HindIII 
(Boehringer Mannheim) in buffer Tango. (For details on 
digestion reactions, see table A2 in the Appendix).All 
digestion reactions were incubated at 37 ºC overnight.
Ligation of flaA /napA fragments into pML-
λPL vector
The expression vector pML-λPL was ligated with the 
flaA/nap inserts using T4 Ligase and ligation buffer from 
Fermentas. Reaction I (NAP) consisted of 8 µl vector 
(pML-λPL, 6.2 ng/µl), 22 µl insert (napA, 1.5 ng/µl), 
10x ligation buffer and 1 µl Ligase. Reaction II (FlaA) 
consisted of 8 µl vector (pML-λPL, 6.2 ng/µl), 13 µl 
insert (flaA, 7.5 ng/µl), 10x ligation buffer and 1 µl 
Ligase. The ligation reactions were incubated at 22ºC 
overnight. 
Purification of PCR product from agarose gel
Bands from agarose gels were purified using the 
E.Z.N.A™ Cycle-Pure Kit from Omega Bio-Tek. The 
gel piece was melted at 50 ºC in QX1 Buffer from the 
QIEAII Gel Extraction Kit (Qiagen), and this sample 
was used in DNA purification according to the 
E.Z.N.A™ Cycle-Pure Protocol. The concentration of 
the eluted DNA was determined by NanoDrop as 
described above.
Expression of NAP and FlaA
Cell cultures: growth, induction and 
fractioning.
All incubations were performed with shaking (180 rpm). 
Cells were grown in 1.5x LB-Amp at 30 °C overnight to 
make pre-cultures. Pre-cultures were diluted 1:100 in 1.5 
x LB-Amp, and then incubated for 4 h before dividing it 
in two separate cultures. Recombinant protein 
expression was induced in one of the cultures by raising 
the temperature to 42 °C. The induction time was 3 h for 
all cultures. Both induced and non-induced cultures were 
centrifuged at 10 000 x g at 4 °C for 20 minutes, and the 
bacterial pellets were dissolved in PBS.  The bacterial 
suspension was mixed with lysozyme (1 mg/ml) and 
EDTA (to a final concentration of 5 mM), and incubated 
for 10 minutes at room temperature (in which time the 
suspension should become viscous due to the presence 
of lysed cells that release their DNA). MgCl2 (to a final 
concentration of 20 mM) and a small amount of solid 
DNase were added, and left to stand for 10 min at r.t. (in 
which time the viscosity should disappear). The lysate 
was ultra-sonically treated (60 Amp, 2 x 4 min, pulser 2 
sec) and then checked under the microscope (to make 
sure that there were no intact cells left). The sonicate 
was centrifuged at 600 x g at 4 °C for 10 minutes, and 
the pellet (cellular debris) was dissolved in PBS. The 
supernatant was centrifuged at 5000 x g at 4 °C for 10 
minutes, and the pellet (inclusion bodies)  was dissolved 
in PBS. The resulting supernatant was ultra-centrifuged 
at 76 000 x g for 30 minutes to separate the membrane 
fraction (pellet)  from the cytosolic sample (supernatant). 
The total protein samples, sub-cellular fractions and 
cultivation medium were analysed using SDS-PAGE and 
Western blotting. 
SDS-PAGE 
The NuPAGE® electrophoresis system from Invitrogen 
were used for SDS-PAGE according to the NuPAGE® 
Technical Guide. Each sample was mixed with an equal 
volume of 2x sample buffer, and 10 µl were loaded into 
each well of a NuPAGE® 12 % Bis-Tris gel. 8µl All Blue 
protein ladder from BIO-RAD (Appendix, fig. A1) was 
used as standard. The gel was run in 1x MOPS buffer 
(50 ml 20 x NuPAGE MOPS SDS Running Buffer, 950 
ml dH2O)  at 200 V for 50 min. The gel was either used 
in western blotting or Coomassie staining. The gel was 
stained in Coomassie 0.25 % Brilliant BlueR-250 
Staining Solution for 2 h (or overnight), and incubated in 
Destaining Solution (10 % HAC, 30 % EtOH, 60 % 
H2O) for 3 h. The gel was washed in H2O for 3 x 10 
minutes, and incubated in NuPAGE® Gel Drying 
solution (available from Invitrogen) at gentle agitation 
for 20 minutes. The gel was dried using the NuPAGE® 
DryEase Mini-Gel Drying System from Invitrogen.    
Western blotting
Western Transfer of the gels were performed according 
to the NuPAGE® Technical Guide. The gels were 
transferred in 1x NuPAGE® Transfer Buffer (50 ml 20x 
NuPAGE transfer buffer, 100 ml EtOH, 850 ml dH2O)  at 
30 V for 1 h. All incubation and wash steps were 
performed with gentle agitation. The transfer membrane 
was put in protein blocking solution (1 % BSA in PBS) 
for 30 min (or overnight), and rinsed briefly in PBS. The 
membrane was incubated with primary antibody solution 
(10 ml 0.1% BSA in PBS, 20 µl Tween-20, 500 µl mAb 
FlaA (75 mg/ml)  or mAb NAP (31 mg/ml)  for 2 h (or 
overnight), and washed for 3 x 5 min in wash solution 
(0.05 % Tween-20, PBS). The blot was incubated with 
enzyme conjugated second antibodies (10 ml 0.1% BSA 
in PBS, 20 µl Tween-20, 100 µl Jackson HRP Goat anti-
mouse IgG) for 2 h, and washed 2 x 5 min in wash 
solution containing Tween-20, and 2 x 5 min in PBS. 
The blot was developed in substrate-chromogen solution 
(2 ml alfa-chloro-naphthol in cold methanol, 10 ml TBS 
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Buffer (0.02 M phosphate, 0.15 M NaCl, pH7.5), 6 µl 30 
% H2O2) for 5-15 min. The membrane was rinsed in tap 
water to stop the reaction, and left to dry between filter 
papers. 
Periplasmic preparation
E. coli N4830-I cells harbouring the recombinant 
plasmid (pML-λPL-napA) were used. Starting with 5 ml 
of induced culture, cells were harvested by 
centrifugation (10 000 x g for 20 min)  and suspended in 
1 ml of 20 % (w/v)  sucrose, 0.3 M Tris-HCl, pH 8.0, 1 
mM EDTA, and incubated for 20 min at r.t. The lysate 
was centrifuged at 10 000 for 20 minutes. The resulting 
pellet was suspended in 0.5 mM cold MgCl2 and 
incubated on ice for 15 min, and then centrifuged at 20 
000 x g for 10 min. An aliquot of the periplasmic 
fraction (supernatant) was diluted 10 x and checked for 
NAP with SDS-PAGE. 
Protein purification
Preparation of inclusion bodies
E. coli N4830-I cells harbouring the recombinant 
plasmid (pML-λPL-flaA)  were grown in LB-Amp and 
induced as described above. Samples were collected 
after 2, 3 and 4 h as well as after over night induction, 
for microscopic and SDS-PAGE analyses. Starting with 
one l of 4 h induced culture, cells were harvested by 
centrifugation (10 000 x g for 20 min)  and lysed as 
described above. The inclusion bodies were pelleted by 
centrifugation (3000 x g for 10 min)  and washed in 10 
ml of cold PBS, 10 mM EDTA a total of 3 times. After a 
final centrifugation (6000 x g for 10 min), the inclusion 
body pellet was dissolved in 1 ml dH2O, and mixed 
quickly with 20 ml of 6.5 M Urea, 1 mM EDTA. The 
solution was left at r.t over night at gently rotation to 
dissolve. The next day, the insoluble material was 
removed by centrifugation (27 000 x g for 20 min), and 
the supernatant was dialysed against 10mM Tris-HCl, 
pH 7.5, 50 mM NaCl. The buffer was changed two times 
before and one time after over night dialysis. The 
dialysate was centrifuged at 27 000 x g for 30 min to 
remove any particles. The supernatant and the pellet 
were checked for FlaA protein with SDS-PAGE. An 
alternative strategy was also applied to avoid re-
precipitation of FlaA. Inclusion bodies were pelleted by 
centrifugation (6000 x g for 10 min)  and dissolved in 
dH2O and Urea, as described above. After removal of 
insoluble material, the supernatant was dialysed as 
above, but this time with a stepwise removal of urea. 
Urea concentrations in the buffer were divided by two a 
total of three times (from 1 M to 0.125 M Urea), before 
over night dialysis against 10mM Tris-HCl, pH 7.5, 50 
mM NaCl. After centrifugation of the dialysate (27 000 
x g for 30 min), the supernatant and pellet were checked 
by SDS-PAGE. The supernatant was stored at -20 °C, 
and after thawing the sample, a new centrifugation (48 
000 x g for 30 min) was performed, to confirm the 
localisation of FlaA (soluble or non-soluble fraction).   
Ammonium sulphate precipitation 
All incubation steps were performed at room 
temperature. Starting with 2 l of induced culture, cells 
were harvested and dissolved in 10 ml of 500 mM Tris-
HCL pH 7.5, 1 mM EDTA, 500 mM NaCl. The cells 
were lysed as described above. The lysate was 
centrifuged at 15 000 x g for 20 min, and the resulting 
supernatant was centrifuged again at 15 000 x g for 20 
min. For NAP, the supernatant was made 60 % (w/v) 
saturated with respect to ammonium sulphate. After 
centrifugation (15 000 x g for 45 min) the supernatant 
was dialysed against 10 mM Tris-HCl, pH 8.0, 20 mM 
NaCl, with several buffer changes before and after 
overnight dialysis. The dialysate was concentrated by 
centrifugation (5000 x g for 3 x 10 min)  in a Vivaspin 
(5000 MWCO) spin column. An attempt to purify FlaA 
by ammonium sulphate precipitation was also 
performed. For FlaA, the dialysed supernatant obtained 
from preparation of inclusion bodies was made 30 % (w/
v) saturated with respect to ammonium sulphate. After 
centrifugation (15 000 x g for 45 min), the resulting 
supernatant was made 50 % (w/v) saturated with 
ammonium sulphate. Precipitated material was again 
pelleted by centrifugation (20 000 x g for 45 min). The 
resulting pellets from 30 % and 50% saturation were 
resuspended in 10 ml of 10 mM Tris-HCl, pH 8.0, 20 
mM NaCl. Both of the pellets, and the 50 % supernatant, 
were checked for FlaA protein by SDS-PAGE.
Anion exchange chromatography
Protein purification was performed using the 
UNICORN™ controlled ÄKTAexplorer™ system. The 
dialysed NAP supernatant obtained from ammonium 
sulphate precipitation was applied to a Resource Q 
column that had been equilibrated with 10 mM Tris-HCl, 
pH 8.0, 20 mM NaCl. Proteins were eluted with a NaCl 
gradient generated by mixing the abovementioned buffer 
with 10 mM Tris-HCl, pH 8.0, 1 M NaCl. The eluted 
fractions were resolved by SDS-PAGE. The fractions 
containing NAP were concentrated by use of a vivaspin 
column, and applied in the next purification step (Gel 
filtration). The dialysed FlaA supernatant obtained from 
preparation of inclusion bodies was applied to a 
Resource Q column that had been equilibrated with 10 
mM Tris-HCl, pH 7.5, 50 mM NaCl. Proteins were 
eluted with a NaCl gradient generated by mixing the 
equilibration buffer with 10 mM Tris-HCl, pH 7.5, 1 M 
NaCl. The eluted fractions were analysed with SDS-
PAGE. 
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Gel filtration
The fractions containing partially purified NAP, 
obtained from anion exchange chromatography, were 
pooled and further purified by gel filtration 
chromatography using a Superdex 200 10/30 column, 
and the UNICORN™ controlled ÄKTAexplorer™ 
system. Proteins were eluted with 10 mM Tris-HCl, pH 
8.0, 0.5 M NaCl, and the fractions containing purified 
NAP were resolved by SDS-PAGE, and pooled. 
Determination of protein concentration
The concentration of the target protein in the pooled 
fractions after gel filtration chromatography was 
measured by use of the DC Protein Assay (BIO-RAD) 
and the NanoDrop ND-100 Spectrophotometer. The DC 
Protein Assay was used according to the manufacturer’s 
instructions. BSA dissolved in the same buffer as the 
NAP protein was used for preparation of a standard 
curve.
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An outline are drawn for the cloning and expression of H. pylori NAP and FlaA in E. coli, in fig. 4. 
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Fig. 4. Cloning and expression of H. pylori NAP and Flagellin A in E. coli. Cloning and Sequencing: (A) Primers were 
designed to amplify flaA and napA genes from H. pylori strain SS1. (B) The napA and flaA genes were cloned into the 
pCR vector by TA cloning. (C) The recombinant plasmids were amplified in E. coli XL-1 strain, and extracted by 
plasmid miniprep. (D) Sequencing analysis of napA and flaA fragments. (E) Plasmid DNA were digested by the use of 
restriction enzymes. (F) The target fragments and expression vectors were recovered and ligated. (G) The recombinant 
expression vectors were transformed into E. coli N4830I host cells. Expression and identification of recombinant 
protein: H) Protein expression was induced in N4830I by heat (42 °C ). (I) The molecular weight and output of 
Flagellin A and NAP protein were examined by SDS-PAGE and western blotting. Monoclonal antibodies (mAbs) 
against FlaA and NAP were used as primary antibodies. Jackson HRP-conjugated Goat anti-mouse IgG was used in the 
secondary step.
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The purification protocol for H. pylori NAP is outlined in fig. 5. Attempts to purify H. pylori FlaA are shown in fig.6. 
 











- Protein conc. determination
- dialysis 
- dialysis / concentration
Fig. 5.  Flow scheme, purification of H. pylori NAP.   
Expression
Cell lysis












Fig. 6.  Flow scheme, attempt to purify H. pylori FlaA.
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Results
Cloning of NAP and FlaA
PCR followed by agarose gel electrophoresis 
confirmed both the generation of napA and flaA 
target DNA amplification products, and the 
successful ligation of these into the cloning 
vector to make pCR-napA and pCR-flaA. 
Target fragments of napA and flaA genes with 
expected sizes (napA ~450 bp and flaA ~1530 
bp) amplified from DNA template of 
Helicobacter pylori SS1 strain are shown in 
figure 7. Sequence analysis of the inserts 
identified the correct napA and flaA clones. 
After amplification in the XL-1 strain and 
plasmid miniprep, the napA and flaA genes 
were cut out from the cloning vector with 
rectriction enzymes, and ligated into the 
expression vector pML-λPL to make the 
constructs pML-λPL-napA and pML-λPL-flaA. 
PCR followed by agarose gel electrophoresis 
confirmed the successful restriction enzyme 







































Fig. 7  Agarose gel electrophoresis showing target 
fragments of flaA and napA genes amplified from H. 
pylori SS1 strain using gene specific primers. From left 
to right: (A) 1 Kb ladder, 100 bp ladder, flaA (~1530 bp), 
(B) ladder (100 bp), napA (~450 bp).  Arrows indicate 
the flaA and napA fragments. The sizes of DNA 
standards are labelled on the left. 
Expression of NAP and FlaA
The expression vector constructs pML-λPL-
napA and pML-λPL-flaA were successfully 
electroporated into the E. coli N4830I strain. 
PCR screening and agarose gel electrophoresis 
of clones selected on growth media with amp 
confirmed the presence of napA and flaA 
inserts. The NAP and FlaA proteins produced 
in N4830I-pML-λPL-napA and N4830I-pML-
λPL-flaA induced by heat (42ºC), were detected 
on SDS-gels and immunoblots. Figure 8 and 9 
(see next page) shows the expression of H. 
pylori FlaA and NAP in E. coli, respectively. 
Arrows indicate the 53 kDa FlaA protein band
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Western blot mAb FlaA
A. SDS-PAGE
Coomassie Blue Stain
Fig. 8. Expression of recombinant H. pylori Flagellin A 
protein.  (A)  SDS-PAGE (B) Immunoblot. From left to 
right (both A and B): Protein Standard, cell extract of 
heat-induced (42ºC) E. coli N4830I containing pML-
λPL-flaA, cell extract of non-induced E. coli N4830I 
containing pML-λPL-flaA. Arrows indicate the 53 kDa 
FlaA band, which was present in induced cells but 
lacking in non-induced cells. The sizes of protein 




























































Western blot mAb NAP
    
Fig. 9. Expression of H. pylori NAP protein. SDS-PAGE 
(12 % Bis-Tris gels) analysis of soluble cell extracts of 
N4830I-pML-λPL-napA by Coomassie Staining (A) and 
Western Immunoblotting (B) using mAb NAP. Detection 
was performed using . From left to right (both A and B): 
Protein Standard, cell extract of heat-induced (42ºC) E. 
coli N4830I containing pML-λPL-napA, cell extract of 
non-induced E. coli N4830I containing pML-λPL-napA. 
Arrows indicate the 17 kDa NAP band, which is mainly 
present in the induced cells. The sizes of protein 
standards are labelled on the left.
Characterisation of NAP and FlaA expression
To investigate where NAP and FlaA reside in 
the host cells after induced expression, the 
cultivation media and different cellular 
fractions (obtained according to the 
fractionation by centrifugation described in the 
materials and methods section) were analysed 
by SDS-PAGE and western blot.  The outcome 
of this fractionation showed that the majority 
of the FlaA protein ends up in inclusion bodies
(data not shown), whereas the majority of the 
NAP protein was detected in the soluble 
cytosolic fraction (fig. 10). A periplasmic 
preparation (see materials and methods 
section) was also performed, to find out 
whether NAP is produced as a periplasmic 
protein or not. The resulting fractions were 
controlled by SDS-PAGE, and shown in fig. 
11. The NAP observed in the total cell extract 
was also present in the pellet, but not in the 








































































































































Fig. 10.  SDS-PAGE analysis of induced and non-
induced N4830I-pML-λPL-napA cell extracts, cellular 
fractions, (cell debris pellet, inclusion body pellet, 
cytosolic fraction /supernatant and plasma membrane 
pellet) and growth medium, by Coomassie Staining (A) 
and Western Immunoblotting (B)  using mAb NAP  (see 


















































Fig. 11. The NAP protein is not found in the periplasmic 
preparation. From left to right: Protein standard, cell 
extract of heat-induced (42ºC) E. coli N4830I containing 
pML-λPL-napA, growth medium, supernatant 
(periplasmic proteins)  and pellet after periplasmic 
preparation. The red circle indicates the 17 kDa NAP 
band, which is present in the pellet after periplasmic 
preparation but not in the supernatant (periplasmic 
proteins). The sizes of protein standards are labelled on 
the left.  
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To optimise the expression of FlaA, the effect 
of induction time on FlaA expression was 
explored. Samples of cell culture with E. coli 
N4830I harbouring the pML-λPL-flaA plasmid 
were collected after 2, 3, or 4 h induction at 42 
ºC and 180 rpm agitation, and the rest of the 
cell culture was left overnight. Inclusion body 
count (microscope) and SDS-PAGE both 
showed an increased number of inclusion 
bodies and FlaA expression from 2 to 4 h. Over 
night induction did not improve the FlaA 
expression further. The SDS-PAGE results 
showed an increase in the total amount of 
proteins after over night induction. However, 
the best target protein/total protein ratio was 
observed after 4 h induction. 
Attempts to purify FlaA
Inclusion bodies containing FlaA were isolated 
from the rest of the lysed host cell by 
centrifugation, and dissolved in urea. The 
inclusion body fraction and total cell extract 
were analysed by SDS-PAGE. The results 
showed that the inclusion bodies consisted of 
several proteins, in addition to FlaA. After 
pelleting insoluble material, the solubilized 
inclusion bodies were dialysed against a buffer 
without urea. Since the preparation of inclusion 
bodies only generated partially purified FlaA, 
additional downstream purification was 
needed. Therefore, the dialysed supernatant 
was precipitated using ammonium sulphate 
cuts at 30% and 50 % saturation (w/v), 
followed by centrifugation. SDS-PAGE 
analyses of the resulting 30 % and 50 % pellets 
and the 50 % supernatant, showed that all 
proteins, including FlaA, precipitated at 30%, 
and therefore were lost in the insoluble pellet. 
Next, the dialysed supernatant obtained after 
the preparation of inclusion bodies was applied 
directly to a Resource Q column equilibrated 
with running buffer (10 mM Tris-HCl, pH 7.5, 
50 mM NaCl). Proteins were eluted with a 
NaCl gradient.  The eluted fractions were 
analysed by SDS-PAGE, but no FlaA band 
corresponded to the peaks on the chromato-
gram (data not shown). In another run with 
inclusion bodies on a Resource Q column, the 
pressure in the system became too high. This 
indicated that FlaA tends to re-precipitate and 
thus cause clogging of the column/system. 
Therefore an alternative dialysis approach was 
applied where the dissolved inclusion bodies 
were dialysed against running buffer with 
stepwise removal of urea. This strategy kept 
the FlaA protein in solution, as shown in figure 
12 (A). This result was very promising,  and it 
was planned to continue with this sample in 
anion exchange chromatography. However, 
when the FlaA supernatant (from 27 000 x g 
centrifugation) was stored at -20 ºC overnight, 
and then thawed, the FlaA protein re-
precipitated, and was lost in the insoluble 
fraction. This was confirmed by a  new 
centrifugation at 48 000 x g for 30 min, 
followed by SDS-PAGE of the resulting pellet 


































































Fig. 12. FlaA inclusion body solubilisation (A) and re-
precipitation after freeze-thaw cycle(B). From left to 
right: (A) Protein Standard, supernatant and pellet after 
15000 rpm, (B) Protein Standard, pellet and supernatant 
after 20000 rpm. Arrows indicate the 53 kDa Flagellin A 
protein. The sizes of protein standards are labelled on the 
left. The pellet was dissolved in urea and dialysed 
against running buffer, and the urea concentration was 
lowered stepwise, before centrifugation at 27 000 x g for 
30 min. This procedure kept FlaA in the soluble fraction 
(indicated by the arrow in 10A). When this supernatant 
was kept at -20 ºC, the FlaA protein re-precipitated, and 
FlaA was lost in the insoluble pellet after centrifugation 




To separate NAP from other contaminating 
proteins in the cell extract, an ammonium 
sulphate precipitation was performed (see 
materials and methods section). The 
supernatant was made 60% saturated with 
respect to ammonium sulphate, and SDS-
PAGE analysis of the cell debris pellet, 60% 
supernatant and 60% pellet showed that at this 
saturation, NAP remained in the soluble 
fraction (supernatant), while most of the other 
contaminating proteins precipitated and ended 
up in pellet after centrifugation. Thus, the SDS-
PAGE results in figure 13 shows that many 






















































Fig. 13. SDS-PAGE analysis of ammonium sulphate 
precipitation. From left to right: Protein standard, cell 
debris pellet, 60 % ammonium sulphate pellet, 60 % 
ammonium sulphate supernatant. The red circle indicates 
the 17 kDa NAP band, which is present in the 
supernatant after ammonium sulphate precipitation. The 
sizes of protein standards are labelled on the left. 
Next, the dialysed NAP supernatant obtained 
from ammonium sulphate precipitation was 
applied to a Resource Q column equilibrated 
with  running buffer (10 mM  Tris-HCl, pH 8.0, 
20 mM NaCl). Proteins were eluted by  a NaCl 
gradient. The eluted fractions were analysed 
by SDS-PAGE and NAP was detected in 
fractions 50 to 59. The eluted fractions 
containing NAP were pooled, concentrated 
and resolved by  SDS-PAGE, shown in fig. 14 
(A). 
Then, the pooled fractions obtained from anion 
exchange chromatography were applied to a 
Superdex 200 10/30 gel filtration column. 
Proteins were eluted with 10 mM Tris-HCl, pH 
8.0, 0.5 M NaCl. The eluted fractions were 
analysed by SDS-PAGE, and NAP were 
detected in fractions 35 to 44. The fractions 
containing purified NAP were pooled and 













































Fig. 14. Purification of H. pylori NAP protein. (A) 
Result Resource Q column, (B) Result after Superdex 
200 10/30 column. From left to right: (A) Protein 
Standard, concentrated NAP fractions after anion 
exchange chromatography (Resource Q column), (B) 
Protein Standard, concentrated NAP fractions after gel 
filtration (Superdex column). Arrows indicates the 17 
kDa NAP band. The sizes of protein standards are 
labelled on the left. 
The concentration of the NAP protein in the 
pooled fractions after gel filtration 
chromatography was measured by using the 
NanoDrop ND-100 Spectrophotometer, and 
found to be 0.2 mg/ml. The DC Protein Assay 
results from using the same NAP sample, read 
a concentration of 0.18 mg/ml.
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SDS-PAGE analysis after anion exchange 
chromatography showed that NAP was eluted 
in fractions 50 to 59, which corresponds to one 
of the six peaks on the chromatogram in fig. 
15. Thus, the pooled fractions containing NAP 
were effectively separated from other 
contaminants by this procedure. The SDS-
PAGE analysis after gel filtration showed that 
NAP was eluted in fractions 35 to 44, which 
corresponds to the first and highest peak on the 
chromatogram in fig. 16. The two other peaks 
represent proteins that also were observed as 
bands on the SDS-gel (data not shown), and 
thus were effectively removed by this final 
purification step. The values on the Y-axis in 
fig. 16 are not in the same scale as in fig. 15. 
 NAP
Fig. 15. Chromatogram from purification of H. pylori NAP using anion exchange chromatography. The dialysed NAP 
supernatant obtained from ammonium sulphate precipitation was loaded onto a Resource Q column equilibrated with 
running buffer (10 mM Tris-HCl, pH 8.0, 20 mM NaCl). Proteins were eluted with a NaCl gradient generated by 
mixing running buffer (see above) with elution buffer (10 mM Tris-HCl, pH 8.0, 1 M NaCl). The eluted fractions were 
resolved by SDS-PAGE, and NAP was detected in fractions 50 to 59, which were pooled and applied in gel filtration. 
These fractions represent the NAP peak (blue line) marked by a rectangle in the chromatogram. The Y-axis indicates the 






Fig. 16. Chromatogram from purification of H. pylori NAP using gel filtration. The partially purified NAP fractions 
obtained from anion exchange chromatography (fig. 13) were after concentration and buffer exchange by use of a 
vivaspin column, applied to a Superdex 200 10/30 column. Proteins were eluted with 10 mM Tris-HCl, pH 8.0, 0.5 M 
NaCl buffer. The eluted fractions were pooled and resolved by SDS-PAGE, NAP was detected in fractions 35 to 44, 
represented by the NAP peak marked by a rectangle in the chromatogram. The NAP fractions were pooled and tested 
with Nanodrop and DC protein assay. The two other peaks represent proteins that also were observed as bands on the 
SDS-gel, and thus were effectively removed by this purification step. No other contaminating proteins were observed by 
SDS-PAGE analysis. The Y-axis indicates the absorbance given in mAU (milli absorbance unit). The X-axis indicates 





The aim of this study were to characterize and 
optimise the expression of recombinant NAP 
and FlaA in an E. coli expression system based 
on the λPL promoter, in order to establish 
protein purification protocols for NAP and 
FlaA that led to purified proteins of good 
quantity and quality to be used for vaccine 
development purposes. Both proteins has been 
suggested as strong H. pylori vaccine candidate 
antigens (Dundon et al., 2002, Kabir, 2007). In 
this study, the heat-induced N4830I-pML-λPL 
expression system previously established (see 
introduction section), was used for the 
production of NAP and FlaA. A protocol for 
the purification of recombinantly produced H. 
pylori NAP of good quality, was successfully 
established, although the yield was limited.   
Expression and purification of NAP 
The total and sub-cellular expression of NAP 
was detected  by SDS-PAGE, shown in fig. 11. 
The analysis of the N4830I-pML-λPL-napA 
cultures shows expression of NAP in the 
induced total sample. The presence of NAP in 
the induced cell debris fraction shows that 
some of the protein is lost during the separation 
steps, which could be explained by insufficient 
cell lysis and/or adherence of released NAP to 
cell debris and non-lysed cells. The weak band 
that was seen in the inclusion body fraction is 
probably due to contamination from the cell 
debris fraction. Most importantly, large 
amounts of NAP are found in the cytosolic 
fraction and cultivating medium, the latter 
implies that the protein is released from the E. 
coli cells. However, when I repeated the 
experiment, limited amounts were seen in the 
cultivation medium, indicating that the high 
amounts seen in the initial experiment probably 
was due to release of NAP upon cell lysis. 
Anyhow, the observed localisation of NAP is 
beneficial in the subsequent protein purification 
procedure, since the target protein should 
preferably be in a soluble fraction to avoid the 
need for detergents.
The above-mentioned results confirms what 
has already been reported; that H. pylori NAP 
is localised in the bacterial cytosol and is 
released upon autolysis. NAP can bind to the 
external surface of the outer membrane 
(Namavar et al., 1998). In such a location, 
NAP can mediate the binding of H. pylori to 
the cell surface via interactions with 
carbohydrate (Teneberg et al., 1997). 
Further characterisation of the cellular 
localisation of NAP after expression was 
performed by periplasmic preparation. The 
periplasmic space is the space seen between 
the plasma membrane and outer membrane in 
the Gram-negative bacteria. Periplasmic 
preparation provides a way to  extract 
periplasmic proteins from bacterial cells. When 
the pelleted cells are placed in a hypertonic 
solution (e.g. sucrose), plasmolysis occurs. 
This causes the cell to loose water, the plasma 
membrane to shrink, and will also increase the 
permeability of the outer membrane. 
Subsequent adding of ice-cold MgCl2 makes 
the plasma membrane swell, and press out the 
periplasmic proteins. The effect of periplasmic 
preparation can be exploited in the purification 
of periplasmic proteins. Thus, I wanted to 
check whether NAP was a periplasmic protein, 
since the cellular localisation of H. pylori NAP 
remains a subject of debate. The outcome of 
this experiment shows that NAP does not 
reside in the periplasmic preparation (fig. 10), 
hence the recombinant H. pylori NAP is not a 
periplasmic protein.    
One of the earliest forms of protein purification 
was the use of ammonium sulphate 
precipitation. By increasing the concentration 
of ammonium sulphate in steps, differential 
preparation of the protein mixture will occur. 
Centrifugation of the precipitate results in 
“cuts”  of protein populations, significantly 
enriching the purity of the starting material. 
The precipitate will normally resolubilize once 
the salt is removed, either by filtration, or by 
dialysis. Recent studies have reported the use 
of ammonium sulphate precipitation as an 
initial step in the purification of H. pylori NAP. 
However, the studies contradict each other in 
the case of whether NAP ends up in the 
precipitate, or remains in the soluble fraction. 
Kottakis et al. reported that NAP remained in 
solution after a 98% precipitation with respect 
to ammonium sulphate (Kottakis et al., 2007). 
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Ceci et al., on the other hand, reported that 
with two ammonium sulphate cuts at 30% and 
60%, NAP precipitated at 60% concentration
(Ceci et al., 2007). The studies also differed 
with regard to the subsequent purification steps 
used to purify H. pylori NAP. In this study, the 
result of ammonium sulphate precipitation 
shows that NAP remains in solution 
(supernatant) after 60% saturation with respect 
to ammonium sulphate (fig. 13). The outcome 
of this purification step  also shows that the 
majority of contaminating proteins ends up in 
the 60% precipitate (pellet), and are effectively 
removed by this procedure. With more time 
available to optimise this purification step, I 
would suggest a strategy of testing different 
ammonium sulphate cuts, in order to minimise 
the potential loss of NAP to the precipitate. 
Anyhow, the comparison of protein purity by 
SDS-PAGE, shows  a remarkable difference 
before and after the use of ammonium sulphate 
precipitation. With NAP already in a soluble 
fraction, and no need for detergents, 
chromatography techniques was a natural 
choice for the next purification step. After 
dialysis against running buffer followed by 
concentration, the sample was run on a 
Resource Q anion exchange column. The 
eluted fractions containing NAP were pooled, 
dialysed and concentrated, and this sample 
were applied to a Superdex 200 gel filtration 
column. SDS-PAGE analyses after anion 
exchange chromatography (fig. 14 A) and gel 
filtration (fig.14 B) confirmed the presence of 
NAP in the eluted fractions corresponding to 
the NAP peaks marked in the chromatograms 
(fig.15 and 16). Overall, the results shows that 
the number of contaminating proteins is 
effectively reduced by the two chromatography 
steps. The final sample contains NAP of good 
quality (high purity), since no other proteins 
than NAP are detected in the pooled fractions 
after gel filtration. The protein concentration 
was determined by use of the Nanodrop 
ND-100 spectrophotometer, and the DC 
Protein Assay. The values obtained from the 
different methods were similar, hence the 
observed protein concentrations, although quite 
low, are reliable. Considering the initial 
expression level observed for NAP, which was 
very good, the limited yield (0.2 mg/ml) after 
the purification procedure, is surprising. From 
this overall result it is clear that a large amount 
of NAP is lost throughout the purification, 
possibly due to insufficient disruption of cells 
and/or too many buffer changes and 
centrifugation steps. With more time to 
improve the output of recombinant NAP, I 
would suggest further optimalisation 
experiments that explore the effect of changing 
the various parameters, e.g. expression (growth 
and induction time), cell disruption (sonication 
and enzymatic lysis), ammonium sulphate 
precipitation (different cuts), dialysis (less 
buffer changes and centrifugations/filtrations), 
chromatography (change buffers and columns).
Expression and purification of FlaA
To optimise the expression of FlaA, the effect 
of induction time on FlaA expression was 
explored. Cells were induced 2, 3 or 4 h, as 
well as over night, and the results were 
observed by microscopic and SDS-PAGE 
analysis, which clearly shows an increased 
FlaA expression level from 2 to 4 h. In the 
microscope, it was observed that both the size 
and number (one or two) of inclusion bodies 
per bacteria increased. The sizes of the FlaA 
protein bands on the SDS-gel increased 
correspondingly, and it was concluded that 4 h 
induction gives the best target protein/total 
protein ratio, since over night induction mainly 
resulted in larger amounts of the contaminating 
proteins, and not FlaA. 
To further characterise the expression of FlaA, 
different cellular fractions were analysed by 
SDS-PAGE. The outcome of this fractioning 
shows that majority of the FlaA protein ends up 
in inclusion bodies. It should however be 
pointed out that the vast majority of the FlaA 
protein was pelleted already after 600 x g 
centrifugation and not, as expected, after the 
subsequent 5000 x g centrifugation. This was 
probably due to insufficient lysis of the cells 
and/or the formation of high molecular weight 
inclusion bodies.
SDS-PAGE analysis of the cell extract and 
isolated inclusion bodies, comparing the  total 
protein amount of the two, shows that the 
purity did not improve much after preparation 
of inclusion bodies. This indicates that the 
inclusion bodies contain other proteins besides 
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FlaA, and not, as expected, consist mainly of 
the over-expressed target protein. 
Ammonium sulphate precipitation worked very 
well for purifying NAP in a soluble fraction, 
and this technique was also tested with FlaA. 
However, SDS-PAGE analysis of the pellets 
and supernatant from 30% and 50% cuts with 
ammonium sulphate, shows that FlaA 
precipitates and ends up in the insoluble 30% 
pellet. Therefore, the dissolved inclusion 
bodies were dialysed against running buffer, 
and applied directly to a Resource Q anion 
exchange column, in an attempt to further 
purify FlaA. In one experiment, the 
concentration of the sample by a vivaspin 
column before the run, resulted in visible 
particles of precipitated protein. To prevent 
high pressure in the system, particles were 
pelleted by thorough centrifugation of the 
sample. Despite several attempts with different 
running buffers (pH, salt), and trying to avoid 
concentrating steps, FlaA proteins re-
precipitated. This, in turn, created problems 
with particles clogging the column, and loss of 
significant amounts of FlaA in insoluble 
fractions during the dialysis, centrifugation and 
chromatography steps. The initial expression 
level of FlaA observed on SDS-gels was not as 
high as observed for NAP. This, in addition to 
the problems I experienced with precipitation 
throughout the purification procedure, 
contributed to a very small output of FlaA in 
the eluted fractions after anion exchange 
chromatography. Overall, the results of the 
FlaA experiments show that it is hard to purify 
this protein in its native form. The lack of 
recent publications concerning purification of 
recombinant H. pylori FlaA (few or none to my 
knowledge), might indicate that this is a 
challenge yet to be overcome by scientists. The 
purification problems with FlaA in this study, 
are possibly explained by the structural role of 
this protein.  When building up the flagellar 
filament, flagellin polymerize (with itself, and 
possibly other proteins, the latter can also 
explain the contamination of other proteins in 
the inclusion bodies), and therefore tend to 
precipitate into insoluble complexes. Flagellin 
is known to be a protein that arrange itself in a 
hollow cylinder to form the filament of the 
bacterial flagellum. The filament consists of a 
long homopolymer of a single protein, 
flagellin, with a small cap protein at the end. 
Polymerization of flagellin occurs as a result of 
relatively conserved structures at the N and C 
termini, although the intervening regions of the 
protein are highly diverse (Donnelly and 
Steiner, 2002). In 2001, the crystal structure of 
a central proteolytic fragment of Salmonella 
flagellin was solved, contributing to an 
understanding of how these conserved 
structures are involved in filament formation 
(Samatey et al., 2001).
The purification strategy involving inclusion 
bodies was not very successful in this study, 
for reasons unknown. A lesson to be drawn 
from this might be that  we should rethink the 
whole strategy of expression and purification 
of FlaA. Various alternative purification 
procedures can be thought of, e.g. directing the 
recombinant H. pylori FlaA to specific 
compartments, or to the flagellum of the E. coli 
host cell. What about the use of fusion proteins 
such as His-tags? Could other bacterial species 
be better hosts for expressing recombinant 
FlaA? Or maybe the best strategy to obtain 
FlaA in a pure, native form is to knock the 
flagellum directly of the H. pylori, and use the 
crude preparation for immunisation? In 1989, 
Geis et al. isolated the flagella of C. jejuni by 
mechanical shearing from the cell surface, 
sucrose density gradient centrifugation, and 
Sepharose CL-4B gel chromatography (Geis et 
al., 1989). The role of FlaA in H. pylori 
virulence and colonisation has already been 
mentioned(Kabir., 2007), but the potential of 
this antigen in vaccine development remains to 
be investigated. In a recent study, mice 
immunized with a preparation enriched for H. 
pylori flagella sheath proteins exhibited 
significantly reduced colonisation, equivalent 
to that observed in mice immunized with 
whole-cell lysate (Skene et al., 2007).
For more than ten years a vaccine against 
Helicobacter pylori har been the elusive goal 
of many investigators. Although attempts to 
produce a vaccine against H. pylori have failed 
in their ultimate goal, considerable knowledge 
has been developed on the pathogenesis and 
immunity of Helicobacter infections. Marshall 
and Schoep even suggests an alternative use of 
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this knowledge, namely, the use of 
Helicobacter species to deliver vaccines 
against other organisms (Marshall and Schoep, 
2007).
Based on the very high prevalence diseases 
caused by H. pylori,  and the emerge of 
antibiotic resistance among clinical isolates, 
there is a need for an effective vaccine against 
H. pylori. An important part of this vaccine 
development process will be to identify the 
main protective immune mechanisms against 
H. pylori. Several vaccine development 
strategies are currently being explored. One 
such  strategy involves to make a cocktail of 
strong protective antigens, or a recombinant 
bacterial strain that express such antigens, that 
could be  administered by a regimen that gives 
rise to effective immune responses in humans 
(Svennerholm and Lundgren, 2006). Potential 
H. pylori antigens to include in such a cocktail, 
would be NAP, H. pylori adhesin A (HpaA), 
Urease B subunit (UreB), and FlaA. 
Conclusion
In this study, H. pylori Neutrophil-activating 
protein (NAP) and Flagellin A (FlaA) were 
cloned and expressed in E. coli N4830I-pML-
λPL-napA and N4830I-pML-λPL-flaA, 
respectively. The majority of the produced 
FlaA protein ended up in inclusion bodies, 
whereas the majority of the NAP protein was 
detected in the soluble cytosolic fraction. NAP 
was purified by a combination of ammonium 
sulphate precipitation, anion exchange 
chromatography and gel filtration, resulting in 
recombinant NAP with good quality (high 
purity), although the yield was limited. 
FlaA was isolated as inclusion bodies, 
however, no downstream purification was 
possible due to problems with re-precipitation. 
This suggests that alternative strategies should 
be considered for the future expression and 
purification of FlaA. Finally, further 
characterisation and optimisation of the protein 
expression are required to develop highly 
effective purification protocols for H. pylori 
NAP and FlaA.
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